Serological mass survey for early detection of nasopharyngeal carcinoma in wuzhou city, china

Zeng, Yi; Jan, M. G.; Zhang, Q.; Zhang, L. G.; Li, H. Y.; Wu, Yixuan; Wang, Y. S.; Su, Guoming

doi:10.1002/ijc.2910290204

Cited by 192 publications

(167 citation statements)

References 2 publications

Supporting

Mentioning

163

Contrasting

Unclassified

Order By: Relevance

“…Previous population studies carried out in high-incidence areas for NPC estimated the occurrence of the cancer among apparently healthy subjects having an elevated serum level of VCA IgA to be about 1% per year. 4,5,7 In practice, this serves to alert the individuals and clinicians to early symptoms of the cancer.…”

Section: Discussionmentioning

confidence: 99%

Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum

Cheng

Chan

Chen

et al. 2001

Intl Journal of Cancer

View full text Add to dashboard Cite

We have evaluated the performance of 3 new EBV ELISA for the diagnosis of nasopharyngeal carcinoma (NPC). The tests were specific for EBNA 1 IgA, EBNA 1 IgG and zta IgG, respectively. Their distinct antigenic specificity permits these assays to be used in concert in an approach that differentiates patients and apparently healthy subjects on the basis of their antibody spectrum. By so exploiting a distinguishing feature of NPC first described by the late Werner Henle that the patients sustain high levels of a broad spectrum of serum EBV antibodies, this approach achieved a sensitivity of 92% and a specificity of 93%, surpassing the performance of each of these assays individually. The enhanced performance is especially useful in population screening. It was shown that relative risk of NPC sustained by apparently healthy subjects residing in a high incidence area for NPC in the Pearl River estuary in Southern China may vary according to EBV antibody spectrum. The risk of the cancer was markedly reduced with odds ratios of 0.009 for 59% of those who had low level of all 3 antibodies. The risk was increased as antibody spectrum broadens and the risk was the highest with an odds ratio of 138 for 0.4% of those who had high levels of all 3 antibodies. Thus, EBV antibody spectrum may serve to guide follow-up measures for early detection of the cancer and/or risk counseling according to level of the risk of the cancer sustained by the screened individuals.

show abstract

Section: Discussionmentioning

confidence: 99%

Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum

Cheng

Chan

Chen

et al. 2001

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…58 In fact, a panel of serological tests is used fairly successfully to screen for nasopharyngeal carcinoma in high risk populations, to assign prognosis in those patients who are affected, and to detect early relapse after therapy. 59 Analogous studies are underway in gastric carcinoma patients who likewise harbor high serological titers against EBV.…”

Section: Ebv Serologymentioning

confidence: 99%

Molecular Diagnosis of Epstein-Barr Virus-Related Diseases

Gulley

2001

The Journal of Molecular Diagnostics

293

237

View full text Add to dashboard Cite

Epstein-Barr virus (EBV) is the causative agent of in-fectious mononucleosis, and it may also be found in a wide variety of benign and malignant lesions including oral hairy leukoplakia, inflammatory pseudotumor, Hodgkin's disease, non-Hodgkin's lymphoma, nasopharyngeal carcinoma, and gastric carcinoma. Molecular testing is increasingly important in the diagnosis and monitoring of patients affected by these diseases. In biopsy tissues, molecular detection of EBV-encoded RNA transcripts by in situ hybridization remains the gold standard for proving that a histopathological lesion is EBV-related. EBV-encoded RNA hybridization and EBV LMP1 immunostains are used routinely to detect latent EBV in tissues affected by posttransplant lymphoproliferative disorder (PTLD) or in enlarged nodes from patients with infectious mononucleosis. Traditional serology is the best test for evaluating acute versus remote infection in healthy individuals. High serological titers serve as a tumor marker for some EBV-related malignancies, but titers are not a dependable tumor marker in immunocompromised hosts. EBV viral load testing by quantitative DNA amplification of blood samples is a promising new laboratory test that has proven useful for early diagnosis and monitoring patients with PTLD. Recent studies suggest a role for EBV viral load testing in nasopharyngeal carcinoma, Hodgkin's disease, and AIDS patients with brain lymphoma. Further research is needed to define more fully the clinical utility of viral load tests in the full spectrum of EBV-associated diseases. Gene expression profiling is on the horizon as a means to improve subclassification of EBV-related diseases and to predict response to therapy. In subsequent decades, EBV has been linked to a wide variety of benign and neoplastic diseases. Nasopharyngeal carcinomas and posttransplant lymphoproliferative disorders are nearly always EBV-associated, whereas several other tumors, such as Hodgkin's disease, nonHodgkin's lymphoma, lymphoepithelioma-like carcinoma, gastric adenocarcinoma, and several types of sarcoma, are less uniformly EBV-associated. 2-7 EBV causes benign transient lymphoproliferative lesions at the time of primary infection, and it is found in a benign lesion of the tongue called oral hairy leukoplakia. 8,9 Patients affected by these benign or malignant diseases may benefit from laboratory detection of EBV to confirm their diagnosis or to monitor disease burden after the initiation of therapy.Laboratory detection of EBV is accomplished in several ways (Table 1), and recent progress has focused on the molecular analysis of viral DNA and RNA. In situ hybridization has long been considered the gold standard for detecting tumor-associated viral infection, and EBV viral load assays are now being adopted for clinical evaluation of tumor burden in affected patients. This review article summarizes the pathobiology of EBV infection and describes the clinical laboratory tests that are used to assist in diagnosis and monitoring of patients with EBV-related diseases. The ...

show abstract

“…1 Although several previous studies [2][3][4][5] have reported on the use of EBV serology for screening and early detection of NPC, the role of EBV DNA detection as a screening test for NPC remains to be defined. Circulating cell-free EBV DNA is detectable in the plasma of 96% of NPC patients 6 by quantitative real-time polymerase chain reaction (PCR) and has been shown to be a useful marker in prognostication 7 as well as residual disease detection.…”

Section: Dear Sirmentioning

confidence: 99%

Plasma Epstein‐Barr virus (EBV) DNA: Role as a screening test for nasopharyngeal carcinoma (NPC)?

Wong

Lai

Tsui

et al. 2005

Intl Journal of Cancer

View full text Add to dashboard Cite

Dear Sir,We read with interest the recent article in this journal on screening for family members of nasopharyngeal carcinoma (NPC) patients by serologic tests against Epstein-Barr virus (EBV). 1 Although several previous studies [2][3][4][5] have reported on the use of EBV serology for screening and early detection of NPC, the role of EBV DNA detection as a screening test for NPC remains to be defined. Circulating cell-free EBV DNA is detectable in the plasma of 96% of NPC patients 6 by quantitative real-time polymerase chain reaction (PCR) and has been shown to be a useful marker in prognostication 7 as well as residual disease detection. 8 Studies on EBV DNA detection, however, are performed on known NPC patients but not in the general population. We report our preliminary results on plasma EBV DNA detection, in association with EBV serology, as screening tests for NPC in the setting of routine health assessment.In the 6-month period from July to December 2004, a total of 1,475 blood samples were referred from the Health Assessment Centre of our hospital for detection of EBV status as part of body checkup. They comprised 875 male patients and 600 female patients with a median age of 49 years (range 16-92 years). None of them had prior history of EBV-related malignancies. All patients were tested for cell-free plasma EBV DNA level, and when the result was positive, serum samples were retrieved for EBV serologic testing.The RealArt EBV LC PCR Kit (Artus, Hamburg, Germany), working on the LightCycler instrument (Roche Diagnostics, Mannheim, Germany), was employed for plasma EBV DNA detection. The EBV LC PCR Master reagent contained reagents and enzymes for the specific amplification of a 97 bp region of the EBNA1 gene of the EBV genome. Quantification standards were provided with the kit and were included in each run so as to generate the standard curve for EBV load determination. An external quantified EBV viral DNA control (Advanced Biotechnologies, Columbia, MD) was included in each run to check the performance of the assay. Serum EBV VCA IgA and EA IgA antibody levels were determined by indirect immunofluorescence assay on Raji cells and B95-8 cells induced to express EA and VCA, respectively (purchased from the Department of Microbiology, The University of Hong Kong). Antibody titer was defined as the highest dilution that yielded a positive fluorescent signal. Cutoff values for positivity were set at 1:40 for VCA IgA and 1:10 for EA IgA.The presence of EBV DNA was detected in 33 patients (2.24%). Among them, 4 were positive for VCA IgA in which 1 patient was also positive for EA IgA. The clinical records of these patients were reviewed. The only patient with detectable EBV DNA (118 copies/mL) and positive VCA (titer 1:80) as well as EA (titer 1:40) IgA was a 48-year-old man who was referred for otorhinolaryngology (ENT) consultation. Endoscopic examination of the nasopharynx and biopsy showed undifferentiated carcinoma consistent with NPC. Another patient, a 20-year-old man who showed detectable EBV DNA (4...

show abstract

Serological mass survey for early detection of nasopharyngeal carcinoma in wuzhou city, china

Cited by 192 publications

References 2 publications

Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum

Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum

Molecular Diagnosis of Epstein-Barr Virus-Related Diseases

Plasma Epstein‐Barr virus (EBV) DNA: Role as a screening test for nasopharyngeal carcinoma (NPC)?

Contact Info

Product

Resources

About